Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + chidamide + gemcitabine for PD-1 progressed advanced squamous NSCLC
ChiCTR2400090083Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Sep 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab, tucidinostat and gemcitabine in Pulmonary squamous cell carcinoma, sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Overall response rate and Adverse events. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
adebrelimabtucidinostatgemcitabine
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2400090083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090083.